ACID CERAMIDASE, CERAMIDE & FARBER DISEASE

酸性神经酰胺酶、神经酰胺

• 批准号: 7992518
• 负责人: EDWARD H. SCHUCHMAN
• 金额: $ 2.5万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-01-01 至 2010-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7992518
• 关键词: Affect; Affinity; Affinity Chromatography; Animals; Biochemical; Biological Assay; Breeding; Cell Survival; Cells; Ceramides; Chinese Hamster Ovary Cell; Complex; Development; Embryo; Embryonic Development; Enzymes; Farber' s lipogranulomatosis; Fertilization; Gene Proteins; Gene Targeting; Genes; Genotype; Germ Cells; Goals; Growth; Human; Hydrolase; Immunofluorescence Immunologic; In Situ; In Situ Hybridization; In Vitro; Individual; Knock-out; Knockout Mice; Lead; Length; Ligands; Lipids; Mediating; Metabolism; Molecular Chaperones; Multienzyme Complexes; Mus; Partner in relationship; Pathogenesis; Patients; Pattern; Phorbol Esters; Physiological; Property; Proteomics; Purkinje Cells; RNA; Reagent; Recombinants; Research; Role; Signal Transduction; Sphingolipids; System; Transgenic Mice; Western Blotting; acid sphingomyelinase; analog; animal breeding; blastocyst; cell growth; embryonic stem cell; galactosylgalactosylglucosylceramidase; inhibitor/antagonist; irradiation; large scale production; macrophage; mouse development; mouse model; mutant; novel; overexpression; polypeptide; promoter; recombinase; research study; trafficking; vector

DESCRIPTION (provided by applicant): The overall goals of our research are to investigate the role of acid ceramidase (AC) in sphingolipid metabolism, sphingolipid-mediated signal transduction, and the pathogenesis of Farber disease. Towards this end, we have: a) isolated the full-length cDNAs and genes encoding human and murine AC, b) developed an overexpression/purification system for the large-scale production of the human enzyme, c) extensively characterized the recombinant enzyme, revealing a multienzyme complex consisting of AC, acid sphingomyelinase, and at least one other enzyme involved in ceramide metabolism, and d) constructed the first knock-out mouse model of AC activity. In these latter experiments, no homozygous, affected (ACKO-/-) embryos were found at day E8.5 or later. We now propose to extend these findings by pursuing the following four specific aims: 1) Examine the expression of AC in early mouse development and investigate the mechanism explaining the absence of ACKO-/- embryos. We will document the expression pattern of AC in normal mouse embryos, obtain preimplantation embryos from ACKO+/- intercrosses for genotype analysis and biochemical/morphological characterization, and study the gametes from ACKO+/- animals to uncover potential abnormalities in mutant gametes that might affect fertilization, 2) Construct and characterize AC conditional knock-out mice. We have already constructed an AC gene targeting vector that can be used to produce conditional KO mice. We will next obtain mice that are homozygous for this targeting sequence, and breed them to transgenic mice expressing Cre recombinase under the control of inducible, macrophage-specific, and Purkinje cell-specific promoters. Resulting animals will be characterized clinically, pathologically, and biochemically. 3) Investigate the interaction of AC, acid sphingomyelinase and other lipid hydrolases in a multienzyme complex. We will use novel, sphingolipid affinity ligands to obtain large quantities of the multienzyme complex, and identify new components by a proteomics approach and/or by functional assays, and study the formation and intracellular trafficking of the complex under cell growth conditions known to stimulate sphingolipid-mediated cell signaling, and 4) Use AC-specific inhibitors to investigate the "forward" and "reverse" AC activities, and for the treatment of Farber disease. We will continue to characterize the inhibitory effects of novel sphingolipid analogues in vitro and in situ, and evaluate their use for chaperone therapy of Farber disease.

描述（由申请人提供）：我们研究的总体目标是研究酸性神经酰胺酶（AC）在鞘脂代谢、鞘脂介导的信号转导和法伯病发病机制中的作用。为此，我们已：a）分离编码人和鼠AC的全长cDNA和基因，B）开发用于大规模生产人酶的过表达/纯化系统，c）广泛表征重组酶，揭示由AC、酸性鞘磷脂酶和至少一种参与神经酰胺代谢的其它酶组成的多酶复合物，和d）构建AC活性的第一个敲除小鼠模型。在后面的这些实验中，在E8.5天或更晚的时间没有发现纯合的受影响（ACKO-/-）胚胎。我们现在提出通过追求以下四个具体目标来扩展这些发现：1）检查AC在早期小鼠发育中的表达，并研究解释ACKO-/-胚胎缺失的机制。我们将记录AC在正常小鼠胚胎中的表达模式，从ACKO+/-杂交中获得植入前胚胎用于基因型分析和生化/形态学表征，并研究来自ACKO+/-动物的配子以发现可能影响受精的突变配子中的潜在异常。我们已经构建了一个AC基因靶向载体，可用于生产条件性KO小鼠。我们接下来将获得这种靶向序列的纯合小鼠，并将它们培育成在诱导型、巨噬细胞特异性和浦肯野细胞特异性启动子控制下表达Cre重组酶的转基因小鼠。将对所得动物进行临床、病理学和生化表征。3)研究AC、酸性鞘磷脂酶和其他脂质水解酶在多酶复合物中的相互作用。我们将使用新的鞘脂亲和配体来获得大量的多酶复合物，并通过蛋白质组学方法和/或通过功能测定来鉴定新的组分，并在已知刺激鞘脂介导的细胞信号传导的细胞生长条件下研究复合物的形成和细胞内运输，以及4）使用AC特异性抑制剂来研究“正向”和“反向”AC活性，以及用于治疗法伯病。我们将继续表征新型鞘脂类似物在体外和原位的抑制作用，并评估其用于Farber病的分子伴侣治疗。